A few months ago, the father of marijuana research, Professor Raphael Mechoulam, unveiled his newest discovery: the cannabidiolic acid (EPM 301). His introduction of the latest, patented substance caused much excitement in the marijuana industry, especially within the medical cannabis sector. His compound is entirely stable, synthetic, and an acid-based cannabinoid molecule. It was announced to the world in collaboration with EPM, a global biotechnology company in America. EPM seeks to bridge the gap between the pharmaceutical industry and the cannabis market.
Legal on paper, restricted in practice. Inside Germany’s cannabis system, where cultivation is allowed but…
The idea may sound strange: a tobacco plant producing compounds like psilocybin or DMT. Sounds…
The term “addiction” gets thrown around quite freely in everyday language—this is nothing new. Who…
Three days before the Trump administration moved medical marijuana to Schedule III, a new YouGov…
On April 23, 2026, the Trump administration officially moved FDA-approved marijuana products and marijuana products…
Here we are in 2026, and a conflict that was supposed to wrap up in…